Open AccessIntra‐articular hyaluronan (Synvisc®, hylan G‐F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised, placebo controlled trial
Author(s) -
Zammit Gerard V,
Munteanu Shan E,
Menz Hylton B,
Landorf Karl B,
Handley Christopher J,
ElZarka Ayman,
DeLuca Jason
Publication year - 2011
Publication title -
journal of foot and ankle research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.763
H-Index - 39
ISSN - 1757-1146
DOI - 10.1186/1757-1146-4-s1-o54
Subject(s) - medicine , osteoarthritis , hyaluronic acid , viscosupplementation , orthopedic surgery , sodium hyaluronate , placebo , physical therapy , arthropathy , rheumatology , randomized controlled trial , surgery , intra articular , alternative medicine , pathology , anatomy
Methods One hundred and fifty one (n=151) participants with symptomatic first MTPJ OA were randomly allocated to receive up to 1ml intra-articular injection of either Synvisc, hylan G-F 20 or a sterile saline placebo. Outcomes were evaluated at 1, 3 and 6 months post-injection. Primary outcome measurements included the foot pain and foot function sub-scales of the Foot Health Status Questionnaire (FHSQ). Secondary outcome measurements were pain at the first MTPJ during walking and rest, self-reported stiffness at the first MTPJ, magnitude of symptom change with allocated treatment, global satisfaction, health-related quality of life (assessed via the Short-Form-36, version two), first MTPJ dorsiflexion range of motion, strength of the hallux plantarflexors, use of pain-relieving medication, concomitant therapies and dynamic plantar pressures.